Personalis Inc Stock News

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

Tempus AI pledged to buy cancer diagnostics outfit Personalis for $1.5 billion on Monday. But shares of both medtech companies skidded.

Tempus AI (NASDAQ:TEM) will acquire Personalis (NASDAQ:PNSL) in a stock deal valued at $1.5 billion, expanding its reach in the market for tests that monitor cancer recurrence after treatment. Personalis shareholders will receive $16.25 per share, a 6% premium to Friday's closing price and a 28% premium to the unaffected 30-day volume-weighted average price.

Tempus AI, a healthcare tech company, is a favorite of investor Cathie Wood. Personalis does cancer testing.

Tempus ​AI said ‌on Monday ​it ​would acquire ⁠Personalis ​for about $1.5 ​billion to bringing ​its ​cancer test ‌to ⁠the AI-enabled precision ​medicine ​firm's ⁠oncology portfolio.

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that it has entered into a definitive agreement to acquire Personalis, Inc. (NASDAQ: PSNL). The acquisition will expand Tempus' capabilities in minimal residual disease (MRD) and enhance its ability to support patients from diag...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that it has achieved UKCA (United Kingdom Conformity Assessed) marking for its NeXT Personal Dx test. This critical regulatory milestone enables the clinical use of Personalis' ultrasensitive Minimal Residual Disease (MRD) detection technology across Great Bri...

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union's In Vitro Diagnostic Regulation (IVDR). The CE Mark represents an important regulatory milestone...